金城医药公告，全资子公司北京金城泰尔制药有限公司近日收到北京市药品监督管理局下发的《医疗器 械注册证》，产品为医用妇科凝胶，注册证有效期为2025年11月11日至2030年11月10日。该产品通过在 阴道壁形成保护性凝胶膜，实现物理隔离外界细菌的效果，辅助预防妇科感染性疾病。取得注册证丰富 了金城泰尔的妇科产品线，拓展了女性健康领域的产品布局。 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-078 特此公告。 山东金城医药集团股份有限公司董事会 2025 年 11 月 14 日 山东金城医药集团股份有限公司 关于子公司取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司北京金城泰尔制药有限公司 （以下简称"金城泰尔"）于近日收到北京市药品监督管理局下发的《中华人民 共和国医疗器械注册证》（注册证编号：京械注准 20252180915）（以下简称"《注 册证》"），现将主要内容公告如下： 二、 对公司的影响及风险提示 医用妇科凝胶是由凝胶和阴道给药器两部分组成，通过在阴道壁形成一层保 护性凝胶膜，实现物理隔离外界细菌的效果，从而阻止病原微生物定植。该产品 通过构建阴道壁物理屏障，形成微生物入侵的防护层，辅助预防因细菌、病原微 生物定植引发的妇科感染性疾病（如阴道炎等），为女性阴道健康提供日常防护 或术后修复期的辅助保障。 上述《注册证》的取得丰富了金城泰尔的妇科产品线，拓展了女性健康领域 的产品布局，对公司发展具有积极意义 ...

Group 1 - The company, Jincheng Pharmaceutical, reported that as of October 31, 2025, the total number of shareholders is expected to be 26,613 [1]

证券日报网讯金城医药（300233）11月13日在互动平台回答投资者提问时表示，公司子公司金城泰尔生 产和销售磷酸奥司他韦原料药。其终端制剂产品可以用于甲流的治疗和预防。 ...

Core Viewpoint - Jincheng Pharmaceutical announced the transfer of production technology and licensing rights for "Progesterone Vaginal Soft Capsules" to Haimeini (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million RMB [2] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., is involved in the transaction [2] - The product being transferred is "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baifen®), for which Jincheng Taier holds the drug approval number [2] - The total transaction fee, including tax, is set at 50 million RMB [2]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1][1][1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

格隆汇11月5日丨金城医药（维权）(300233.SZ)公布，公司之全资子公司北京金城泰尔制药有限公司 （简称"金城泰尔"）拟向海默尼（上海）医药科技有限公司（简称"海默尼"）转让所持有的"普罗雌烯 阴道用软胶囊生产技术及上市许可持有人权益"。金城泰尔合法持有"普罗雌烯阴道用软胶囊（商品名： 朗依更宝芬）"的药品批准文号。经交易双方协商一致，标的产品转让的总费用（含税）为人民币伍仟 万元整（￥5,000万元）。双方确认该金额已充分考虑了标的产品权益的实际价值及市场行情等因素。 ...

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and market authorization rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of RMB 50 million [1] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd, is involved in the transaction [1] - The product being transferred is "Progesterone Vaginal Soft Capsules," marketed under the name "Langyigeng Baofen" [1] - The agreed transfer fee of RMB 50 million has been determined based on the actual value of the product rights and market conditions [1]

每经AI快讯，金城医药（SZ 300233，收盘价：17.52元）11月5日晚间发布公告称，公司第六届第十八 次董事会会议于2025年11月4日在公司会议室以现场和通讯相结合的方式召开。会议审议了《关于转让 药品生产技术及上市许可持有人权益的议案》等文件。 2024年1至12月份，金城医药的营业收入构成为：医药制造业占比100.0%。 截至发稿，金城医药市值为67亿元。 每经头条（nbdtoutiao）——36天，美国联邦政府"停摆"创纪录！航空濒临关闭，军饷发放困难，债务 增超6000亿美元...... （记者 张明双） ...